Insulin infusion suppresses while glucose infusion induces toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients

American Journal of Physiology - Endocrinology and Metabolism

Volumn 304, Issue 8, 2013, Pages

  Dandona, Paresh ^a   Ghanim, Husam ^a   Green, Kelly ^a   Sia, Chang Ling ^a   Abuaysheh, Sanaa ^a   Kuhadiya, Nitesh ^a   Batra, Manav ^a   Dhindsa, Sandeep ^a   Chaudhuri, Ajay ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Inflammation

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG INFUSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MONONUCLEAR CELL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTIGENS, CD14; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FATTY ACIDS, NONESTERIFIED; FEMALE; GENE EXPRESSION; GLUCOSE; HMGB1 PROTEIN; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INSULIN; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MIDDLE AGED; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 84878509378     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00566.2012     Document Type: Article

References (43)

1. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 86: 450-453, 2001.
2. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells (Abstract). Nucleic Acids Res 19: 2499, 1991.
3. Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 25: 963-976, 2005.
4. Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109: 849-854, 2004.
5. Churchill ME, Changela A, Dow LK, Krieg AJ. Interactions of high mobility group box proteins with DNA and chromatin. Methods Enzymol 304: 99-133, 1999.
6. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86: 3257-3265, 2001.
7. Dandona P, Ghanim H, Bandyopadhyay A, Korzeniewski K, Ling Sia C, Dhindsa S, Chaudhuri A. Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care 33: 2416-2423, 2010.
8. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet 347: 444-445, 1996.
9. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 57: 3090-3098, 2008.
10. Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56: 2790-2796, 2007.
11. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 52: 1665-1668, 2009.
12. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93: 578-583, 2008.
13. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110: 1564-1571, 2004.
14. Ghanim H, Mohanty P, Deopurkar R, Sia CL, Korzeniewski K, Abuaysheh S, Chaudhuri A, Dandona P. Acute modulation of toll-like receptors by insulin. Diabetes Care 31: 1827-1831, 2008.
15. Gupta S, Koirala J, Khardori R, Khardori N. Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin North Am 21: 617-638, 2007.
16. Hallman M, Ramet M, Ezekowitz RA. Toll-like receptors as sensors of pathogens. Pediatr Res 50: 315-321, 2001.
17. Heinola T, Kouri VP, Clarijs P, Ciferska H, Sukura A, Salo J, Konttinen YT. High mobility group box-1 (HMGB-1) in osteoarthritic cartilage. Clin Exp Rheumatol 28: 511-518, 2010.
18. Hirano M, Osada S, Aoki T, Hirai S, Hosaka M, Inoue J, Ohno S. MEK kinase is involved in tumor necrosis factor alpha-induced NFkappaB activation and degradation of IkappaB-alpha. J Biol Chem 271: 13234-13238, 1996.
19. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761, 1995.
20. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444: 860-867, 2006.
21. Hou CH, Fong YC, Tang CH. HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-kappaB pathways. J Cell Physiol 226: 2006-2015, 2011.
22. Igarashi M, Yamaguchi H, Hirata A, Daimon M, Tominaga M, Kato T. Insulin activates p38 mitogen-activated protein (MAP) kinase via a MAP kinase kinase (MKK) 3/MKK 6 pathway in vascular smooth muscle cells. Eur J Clin Invest 30: 668-677, 2000.
23. Langouche L, Vanhorebeek I, Vlasselaers D, Vander Perre S, Wouters PJ, Skogstrand K, Hansen TK, Van den Berghe G. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115: 2277-2286, 2005.
24. Li P, Cook JA, Gilkeson GS, Luttrell LM, Wang L, Borg KT, Halushka PV, Fan H. Increased expression of beta-arrestin 1 and 2 in murine models of rheumatoid arthritis: isoform specific regulation of inflammation. Mol Immunol 49: 64-74, 2011.
25. Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 47: 532-536, 2004.
26. Marfella R, Di Filippo C, Portoghese M, Ferraraccio F, Rizzo MR, Siniscalchi M, Musacchio E, D'Amico M, Rossi F, Paolisso G. Tight glycemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol 53: 1425-1436, 2009.
27. Michalia M, Kompoti M, Koutsikou A, Paridou A, Giannopoulou P, Trikka-Graphakos E, Clouva-Molyvdas P. Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med 35: 448-454, 2009.
28. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85: 2970-2973, 2000.
29. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 295: 1681-1687, 2006.
30. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GE. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41: 281-288, 2005.
31. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653, 2005.
32. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med In press.
33. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. J Am Med Assoc 302: 1186-1194, 2009.
34. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H. Role of HMGB1 in apoptosismediated sepsis lethality. J Exp Med 203: 1637-1642, 2006.
35. Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S. Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology 198: 35-49, 1997.
36. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 1799: 101-113, 2010.
37. Subramaniam B, Panzica PJ, Novack V, Mahmood F, Matyal R, Mitchell JD, Sundar E, Bose R, Pomposelli F, Kersten JR, Talmor DS. Continuous perioperative insulin infusion decreases major cardiovascular events in patients undergoing vascular surgery: a prospective, randomized trial. Anesthesiology 110: 970-977, 2009.
38. Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 9: 753-762, 2009.
39. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 22: 999-1004, 2005.
40. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52: 2882-2887, 2003.
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment, and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352: 837-853, 1998.
42. Uramoto H, Izumi H, Nagatani G, Ohmori H, Nagasue N, Ise T, Yoshida T, Yasumoto K, Kohno K. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 371: 301-310, 2003.
43. Zhang G, Ghosh S. Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res 6: 453-457, 2000.